Sun Pharmaceutical Industries share price

ABOUT Sun Pharmaceutical Industries

• Industry Biotechnology & Drugs
• ISIN INE044A01036
• BSE Code 524715
• NSE Code SUNPHARMA

Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty, generics and consumer healthcare products. It is engaged in manufacturing, developing, and marketing a range of branded and generic formulations and active pharmaceutical ingredients (APIs). It produces a diverse and complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. It offers a variety of dosage forms, including orals, creams, ointments, injectables, sprays, and liquids. Its global specialty portfolio spans advanced products in dermatology, ophthalmology, and onco-dermatology. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, and others. Its vertically integrated operations deliver medicines to physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents.

Sun Pharmaceutical Industries Management

• C. S. Muralidharan Chief Financial Officer
• Uday Baldota Chief Executive Officer - Taro Pharmaceutical Industries Limited
• S. Damodharan Chief Executive Officer - API Business
• Abhay Gandhi Chief Executive Officer - North America
• Kirti Ganorkar Chief Executive Officer - India Business
• Suresh Rai Chief Human Resource Officer, Senior Vice President
• Dheeraj Sinha Executive Vice President, Chief Information Officer
• Aalok Shanghvi Whole-time Director, Executive Vice-President, Emerging Markets, Global generic R&D, Global BD (Generics Segment) & API
• Jila Breeze Executive Vice President, Global Head - Quality
• Azadar Khan Senior Vice-President, Corporate Relations and Corporate Social Responsibility